TY - JOUR T1 - Prognostic Significance of ZNF217 Expression in Gastric Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 4813 LP - 4817 VL - 34 IS - 9 AU - ATSUO SHIDA AU - SHUICHI FUJIOKA AU - HIDEAKI KURIHARA AU - YOSHIO ISHIBASHI AU - NORIO MITSUMORI AU - NOBUO OMURA AU - KATSUHIKO YANAGA Y1 - 2014/09/01 UR - http://ar.iiarjournals.org/content/34/9/4813.abstract N2 - Background: The zinc finger protein ZNF217 is a candidate oncogene in breast cancer and ovarian clear cell cancer. The purpose of the present study was to clarify the significance of this protein's expression in gastric carcinoma and to evaluate the outcome of these patients. Materials and Methods: Using paraffin-embedded specimens from 84 patients with gastric cancer, ZNF217 protein was detected using an anti-ZNF217 goat polyclonal antibody. We evaluated the ZNF217 protein expression in relation to patient outcome and clinicopathological parameters. Results: The ZNF217 protein was expressed in 34 (40.5%) tumor sections. Patients with ZNF217-negative tumors had better relapse-free survival (RFS) and overall survival (OS) than those with ZNF217-positive tumors by the log-rank test. Notably, multivariate analysis indicated that ZNF217 was an independent prognostic factor for RFS. Conclusion: ZNF217 expression seems to be a novel prognostic biomarker in gastric cancer. ER -